“We continue to make meaningful and measurable progress across our (Z)-endoxifen development strategy in oncology,” stated Steven Quay, Atossa Therapeutics (ATOS)’ Chairman and CEO. “Initiatives include enhanced efficiency, focus and financial discipline with our programs, and readiness as we work to evolve into a commercial company. With a strong balance sheet, a strategically focused team, and the true desire to provide a solution for the millions of women worldwide suffering from breast cancer, we believe we are well-positioned to execute on our planned upcoming IND submission and advance our clinical programs toward key value-creating milestones.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics Advances Breast Cancer Treatment with (Z)-Endoxifen Study
- Atossa Therapeutics Appoints New Chief Financial Officer
- Atossa Therapeutics appoints Mark Daniel as CFO
- Atossa Therapeutics advances global patent strategy for Z-Endoxifen
- Atossa Therapeutics management to meet virtually with Craig-Hallum